Prospective, controlled, double-blind study of i.v. tenoxicam for analgesia after thoracotomy.
We have shown that a single i.v. dose of tenoxicam 20 mg, after thoracotomy, when compared with placebo in 20 patients (with one exclusion), was associated with a reduction in consumption of papaveretum, assessed by patient-controlled analgesia, of 2.2 mg h-1 (22%) to 4 h and 1.4 mg h-1 (23%) to 12 h after operation (repeated measures analysis of variance: P less than 0.01). There was no reduction from 12 to 24 h. There was no significant difference between groups in pain scores or in side effects.
Merry
A F
AF
Department of Anaesthesia, Green Lane Hospital, Auckland, New Zealand.
Wardall
G J
GJ
Cameron
R J
RJ
Peskett
M J
MJ
Wild
C J
CJ
D000328:Adult; D000368:Aged; D000698:Analgesia / Q000379:methods*; D016058:Analgesia, Patient-Controlled; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009892:Opium; D010149:Postoperative Pain / Q000188:drug therapy*; D010894:Piroxicam / Q000031:analogs & derivatives*; D011446:Prospective Studies; D013908:Thoracotomy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D009892:Opium; C032801:tenoxicam